1-25 of 25
Keywords: statin
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles
Clin Sci (Lond) (2017) 131 (9): 791–797.
Published: 19 April 2017
...Allan D. Sniderman; Robert Scott Kiss; Thomas Reid; George Thanassoulis; Gerald F. Watts Statins and PCSK9 inhibitors dramatically lower plasma LDL levels and dramatically increase LDL receptor number within hepatocyte cell membranes. It seems self-evident that total clearance of LDL particles from...
Articles
Clin Sci (Lond) (2015) 128 (7): 411–423.
Published: 09 December 2014
..., which underlie vascular damage in diabetes. Statins are cholesterol-lowering drugs that are vasoprotective in diabetes through unknown mechanisms. We tested the hypothesis that atorvastatin decreases NADPH oxidase (Nox)-derived ROS generation and associated vascular injury in diabetes. Lepr db /Lepr db...
Includes: Supplementary data
Articles
Clin Sci (Lond) (2014) 126 (6): 401–415.
Published: 15 November 2013
...Philip J. Millar; John S. Floras Statins (3-hydroxy-3-methylglutaryl-CoA reductase inhibitors) reduce plasma cholesterol and improve endothelium-dependent vasodilation, inflammation and oxidative stress. A ‘pleiotropic’ property of statins receiving less attention is their effect on the autonomic...
Articles
Clin Sci (Lond) (2013) 124 (5): 343–349.
Published: 16 November 2012
... LDL) (syn LDL3; D =1.044–1.063 g/ml) are increased in diabetes and are closely correlated. We studied whether SD-LDL is more susceptible to glycation in vitro than more buoyant LDL in statin- and non-statin-treated Type 2 diabetes mellitus. Serum SD-LDL apoB and glyc-apoB on statins was 20±2 (means...
Articles
Articles
Articles
Clin Sci (Lond) (2011) 121 (9): 397–403.
Published: 12 July 2011
... with the significant rise in PCSK9 levels after statin therapy, warrant further studies in order to unravel the exact role of PCSK9 in the pathogenesis and treatment of this highly prevalent genetic dyslipidaemia. In addition, a subgroup of FCHL patients ( n =11) also visited our clinic before and after 8 weeks...
Articles
Articles
Articles
Articles
Articles
Articles
Clin Sci (Lond) (2009) 116 (6): 493–495.
Published: 12 February 2009
... [email protected] ). 13 11 2008 27 11 2008 27 11 2008 © The Authors Journal compilation © 2009 Biochemical Society 2009 chronic obstructive pulmonary disease (COPD) dyspnoea endothelin-1 (ET-1) exercise capacity pulmonary hypertension statin So where does...
Articles
Clin Sci (Lond) (2009) 116 (6): 497–505.
Published: 12 February 2009
... disease (COPD) dyspnoea endothelin-1 (ET-1) exercise capacity pulmonary hypertension statin All of the 53 patients performed the exercise test without chest pain or ST-segment depression. Changes in exercise time are shown in Table 3 . The exercise time did not differ between the two...
Articles
Clin Sci (Lond) (2008) 115 (1): 35–42.
Published: 02 June 2008
...Zhen Huang; Leif Jansson; Åke Sjöholm Patients with diabetes are often treated with a statin for hyperlipidaemia and an ACE (angiotensin-converting enzyme) inhibitor or angiotensin receptor antagonist for hypertension or albuminuria. These drugs may also exert beneficial metabolic effects, causing...
Articles
Clin Sci (Lond) (2007) 113 (3): 119–127.
Published: 02 July 2007
...Jennifer H. Martin; Henry Krum HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors (statins) are well-established therapies in the prevention and treatment of cardiovascular disease, reducing all-cause mortality and cardiovascular events in many disease states. Studies have also suggested...
Articles
Articles
Clin Sci (Lond) (2007) 112 (1): 69–76.
Published: 01 December 2006
... treatment may be selectively controlling pancreatic islet blood flow, augmenting insulin secretion and thereby improving glucose tolerance. Our findings indicate significant gender-related differences in the vascular response to these agents. Since statins and renin–angiotensin system inhibitors...
Articles
Clin Sci (Lond) (2006) 111 (1): 87–91.
Published: 14 June 2006
... in smokers with normal lipid levels can be improved by a statin treatment. Correspondence: Dr Stefan Agewall (email [email protected] ). 9 2 2006 27 3 2006 12 4 2006 12 4 2006 Healthy smokers (smoking more than ten cigarettes per day) under the age of 40 years...
Articles
Clin Sci (Lond) (2005) 108 (6): 493–495.
Published: 24 May 2005
... (MAPK) 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor statin Atherosclerosis is currently regarded as a dynamic and progressive disease arising from the combination of endothelial dysfunction and inflammation [ 1 ]. Impairing vascular homoeostasis makes the vasculature susceptible...
Articles
Articles
Articles
Articles
Articles